title: Invasive Fusarium infections: a retrospective survey of 31 cases. The French 'Groupe d'Etudes des Mycoses Opportunistes' GEMO.
abstract: A retrospective study was conducted in France to investigate Fusarium infections which are now recognized as emerging opportunistic infections. The clinical and mycological findings for 31 cases diagnosed between 1984 and 1993 by members of the French Groupe d'Etudes des Mycoses Opportunistes were analysed. All suffered from haematological disease, most often acute leucaemia (n = 19). Twenty-two had received cytostatic chemotherapy and ten had undergone bone marrow transplantation. Prolonged aplasia and pancytopenia were present in 18 and 11 patients, respectively. Skin (61%) and blood (42%) were the sites most frequently involved. Fusarium solani (n = 7), Fusarium oxysporum (n = 7), Fusarium verticilloides (n = 7) were the species most frequently isolated. Nine antifungal treatments were used, associated with colony-stimulating factors in five cases. None was unambiguously superior to all the others. The overall mortality was 51.6% with a specific mortality > or = 25.8%. The disseminated form of the infection was associated with poor prognosis (P < 0.02) whereas improving granulocyte count improved prognosis (P < 0.001). More aggressive cytostatic regimens used for patients with haematological malignancies have favoured the emergence of Fusarium infections. As prognosis is closely correlated with neutrophil recovery, the promising results obtained with the use of colony-stimulating factors should be further evaluated.
authors.affiliation: Service de Microbiologie, Hôpital Necker-Enfants Malades, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Hennequin
authors.forename: V
authors.initials: V
authors.lastname: Lavarde
authors.forename: J L
authors.initials: JL
authors.lastname: Poirot
authors.forename: M
authors.initials: M
authors.lastname: Rabodonirina
authors.forename: A
authors.initials: A
authors.lastname: Datry
authors.forename: S
authors.initials: S
authors.lastname: Aractingi
authors.forename: J
authors.initials: J
authors.lastname: Dupouy-Camet
authors.forename: D
authors.initials: D
authors.lastname: Caillot
authors.forename: F
authors.initials: F
authors.lastname: Grange
authors.forename: L
authors.initials: L
authors.lastname: Kures
authors.forename: O
authors.initials: O
authors.lastname: Morin
authors.forename: B
authors.initials: B
authors.lastname: Lebeau
authors.forename: S
authors.initials: S
authors.lastname: Bretagne
authors.forename: C
authors.initials: C
authors.lastname: Guigen
authors.forename: D
authors.initials: D
authors.lastname: Basset
authors.forename: R
authors.initials: R
authors.lastname: Grillot
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D005260:Female; D005670:Fusarium; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000401:mortality; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000188:drug therapy; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor